Latest Financial Position News

Cauldron Energy’s December quarter report highlights a breakthrough uranium discovery at Manyingee South within the Yanrey Project, alongside a successful $4 million capital raise to fund ongoing exploration.

Lode Resources has completed the acquisition of the Montezuma Antimony Project in Tasmania, delivering high-grade drill results that bolster its strategy to become a leading Australian antimony producer amid global supply shortages.

Aspire Mining Limited has made significant strides in developing its Ovoot Coking Coal Project, progressing construction tenders and customer engagement despite a challenging coal market.

Tolu Minerals reports significant progress in recommencing production and expanding resources at its Tolukuma mine, underpinned by strategic hires and advanced geophysical surveys.

ReNu Energy reports progress on a management buyout proposal for its hydrogen subsidiary and completes sale of legacy geothermal assets, signaling a strategic pivot and ongoing capital challenges.

Kinetiko Energy reports mixed results from its five-well gas production test program, with the first well underperforming but the company maintaining optimism for the remaining wells and a strong financial footing.

Thunderbird Resources has significantly bolstered its portfolio with the acquisition of the Rockvale and Kookabookra antimony-gold projects in New South Wales, alongside promising uranium exploration results in Canada. These developments position the company for a dynamic 2025 exploration season.

Excite Technology Services has achieved positive EBITDA in December 2024, driven by strong revenue growth and record customer receipts, notably from its Digital Forensics division and the integration of CDFS.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.